Pleasanton, Calif. – October 12, 2013 – Azure Biosystems Inc. today introduced the Azure cSeries, the only CCD-based imaging systems that offer gel imaging systems which are fully upgradable to laser-based, IR Western imaging systems. The cSeries flagship product, the c600, is the only Western system in the market that uses lasers diodes for IR imaging, and performs Chemiluminescent and Visible Fluorescent Western blot imaging, making this a unique solution for labs that require application flexibility.
Azure Biosystems designed the cSeries as a modular, upgradable, multi-modal platform. The compact system is built around a touch screen user interface on a tablet computer, offering superior performance and reliability compared to on-board computers. Dual focus technology ensures the lens is always in focus, and always set to the correct settings, providing a simplified imaging experience. The application-driven software controls the many options for integrated light sources including laser diodes for IR 700 and 800 dyes, LEDs for CY5/CY3/CY2 applications, and UV for gel documentation. Chemiluminescent Western performance is achieved with a low noise 8.3 Mega Pixel camera with a 0.95 lens. All cSeries platforms starting with the c200 gel documentation system to the c300, c400, and c500 Western imaging systems can be upgraded in the field to the c600. Thus, customers will not require separate systems for gel documentation, Chemiluminescent Western imaging, Visible Fluorescent Westerns imaging and IR Western imaging.
“The technology for gel and Western imaging systems is evolving,” said Alnoor Shivji, CEO of Azure Biosystems. “The market first started with basic gel documentation systems, and then with the introduction of cooling, developed into Western imaging systems. The third step in this evolution was the personalization of the products, integrating tablet computers, and creating systems with smaller footprints. We consider the Azure cSeries the fourth generation of imaging systems, with the integration lasers and the field upgradeability, in a compact, modular systems as setting a new standard in the industry.”
Azure Biosystems cSeries will begin shipping in November 2013.
About Azure Biosystems
Azure Biosystems Inc. is an innovative life science platform company that designs, develops and markets state of the art imaging platforms such as the cSeries. Azure Biosystems experienced team have developed 2nd and 3rd generation imaging systems for the life science market, thus applying their technical and market knowledge in creating innovative industry standard setting platforms.
For additional information, please see https://www.azurebiosystems.com
Forward Looking Statements
This press release contains certain “forward-looking statements”. Such statements include statements relating to the expected benefits to the Company of using cSeries technology and other statements relating to future events are not historical facts, including statements which may be preceded by the words “will,” “believes” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company. Actual results may differ materially from the expectations contained in the forward-looking statements. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact
Lisa Isailovic
lisa.isailovic@azurebiosystems.com
(925) 307-7127
